In this issue:
Predictive model for infection risk with azacitidine treatment
Factors predicting OS at baseline and during azacitidine in high-risk MDS
Rituximab ±idelalisib, then openlabel idelalisib, for relapsed CLL
TKI de-escalation before discontinuation in CML
The Khorana score for predicting VTE in cancer
Association of early disease progression and very poor survival in follicular lymphoma
High-dose methotrexate for CNS prophylaxis in high-risk DLBCL
Treatment optimisation and genomic outcomes in eltrombopagtreated refractory SAA
Rituximab originator vs. biosimilar in ITP
CV and bleeding outcomes in ITP
Please login below to download this issue (PDF)